Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

The European Commission is seeking feedback from industry players about Novo Holdings' $16.5 billion proposed acquisition of ...

EU antitrust regulators are soliciting feedback from competitors and customers regarding Novo Holdings' proposed $16.5 ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...

European Union antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug ...